Research institution
University of Oxford Clinical Trials
Studies where University of Oxford is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 97Tuberculosis
ID93/GLA-SE Vaccination + BCG Challenge
The purpose of this study is to: 1. Demonstrate the safety of a novel TB vaccine (ID93/GLA-SE) when given to both BCG-vaccinated and BCG-naïve volunteers. 2.
- Trial name
- NCT06670755
- Testing
- ID93/GLA-SE, BCG Danish
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Pre-eclampsia
Oxford Luteal Dysfunction and Placental Insufficiency Study
High blood pressure (BP) affects approximately 1 in 10 pregnancies. About half of women with high blood pressure in pregnancy develop a serious complication called preeclampsia, which kills over 70,000 women and 500,000 babies…
- Trial name
- OxLuPIn (NCT07072052)
- Testing
- No intervention planned
- Where
- United Kingdom
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Spinal Muscular Atrophy (SMA)
Service Evaluation for Newborn Screening for Spinal Muscular Atrophy
Spinal Muscular Atrophy (SMA) is a disease that causes progressive muscle weakness. There are many types- the most severe and most common, type 1, affects very young babies, and is life-threatening if untreated.
- Trial name
- SENS (NCT07888868)
- Where
- 3 sites in United Kingdom
- Volunteers
- 750,000 people
- Sponsor
- University of Oxford
Retinal Vein Occlusion (RVO)
Robotic RVO Trial: Robot-assisted Retinal Vein Cannulation in Patients With Retinal Vein Occlusions
Retinal vein occlusions (RVOs) are the second leading cause of permanent vision loss in the UK. Current treatments, like anti-VEGF injections or steroids, address complications such as macular fluid but do not target the…
- Trial name
- RVO (NCT07820761)
- Testing
- Surgery with Preceyes Robot plus NHS standard of care
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Oxford
Artificial Intelligence Perception and Attitude
What Should we Measure? A Qualitative Interview Study on Outcomes for Evaluating AI-assisted Medical Image Interpretation.
Background: AI (artificial intelligence) tools are increasingly used to help clinicians interpret medical images such as X-rays, scans, skin photographs and eye images.
- Trial name
- NCT07885150
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Vivax Malaria
Southeast Asia Dose Optimization of Tafenoquine
Tafenoquine was recently approved by regulatory authorities in the USA and Australia. Tafenoquine is an alternative radical curative treatment to primaquine acting against the dormant liver stage of Plasmodium vivax (the…
- Trial name
- SEADOT (NCT04704999)
- Testing
- Tafenoquine, Chloroquine, Artemether 20 mg-Lumefantrine 120 mg
- Where
- 6 sites in Cambodia, Indonesia and 3 more
- Volunteers
- 820 people
- Sponsor
- University of Oxford
Major Depressive Disorder (MDD)
Prescribing the Right Agent for Depression in Adults
Depression is a common mental health problem affecting almost 300 million people worldwide. Antidepressants are recommended as one of the first line treatments for people with moderate-to-severe symptoms of depression.
- Trial name
- PRADA (NCT07796295)
- Testing
- PRADA Tool, PETRUSHKA Tool
- Where
- 3 sites in Ethiopia, Pakistan and 1 more
- Volunteers
- 2,142 people
- Sponsor
- University of Oxford
Psychosis, First Episode Psychosis
Stratification and Treatment in Early Psychosis Study - ENHANCE
The purpose of this study is: To investigate whether the response to antipsychotic treatment can be enhanced by adding cannabidiol (CBD) to the existing treatment, compared to placebo, in participants with a first episode of…
- Conditions
- Psychosis, First Episode Psychosis, Psychotic Disorders, Psychotic Episode
- Trial name
- STEP-ENHANCE (NCT06778564)
- Testing
- CBD 100 mg/mL Oral Solution
- Where
- 17 sites in Austria, Germany and 7 more
- Volunteers
- 250 people
- Sponsor
- University of Oxford
Treatment Resistant Psychosis, Psychosis
Stratification and Treatment in Early Psychosis Study -ASSIST
The purpose of this trial is: To investigate whether the response to clozapine treatment can be enhanced by adding cannabidiol (CBD), compared to placebo, in treatment resistant psychosis patients.
- Trial name
- STEP-ASSIST (NCT07326124)
- Testing
- CBD 100 mg/mL Oral Solution, Placeb
- Where
- 15 sites in Germany, Greece and 6 more
- Volunteers
- 250 people
- Sponsor
- University of Oxford
Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis
Stratification and Treatment in Early Psychosis Study - PROMOTE
The purpose of this trial is: To investigate whether cannabidiol (CBD), compared to placebo, can reduce the severity of attenuated psychotic symptoms in individuals at clinical high risk for psychosis.
- Conditions
- Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing Psychosis
- Trial name
- STEP-PROMOTE (NCT07434973)
- Testing
- Cannabidiol (CBD)
- Where
- 19 sites in Austria, Canada and 8 more
- Volunteers
- 586 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Completed, with results posted
All –Psoriatic Arthritis
Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis
MONITOR is a cohort study recruiting patients with a new diagnosis of psoriatic arthritis (PsA) which will establish outcomes using a pragmatic feasible 'treat to target' approach in a real-life clinic population.
- Trial name
- MONITOR (NCT03531073)
- Testing
- Methotrexate
- Where
- United Kingdom
- Volunteers
- 446 people
- Sponsor
- University of Oxford
Locally Advanced Non-Small Cell Lung Cancer
Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC
This is a phase I, open-label trial that will utilise a Time To Event Continual Reassessment Method (TiTE-CRM) to determine the maximum tolerated dose (MTD) of atovaquone in combination with concurrent CRT in NSCLC.
- Trial name
- ARCADIAN (NCT04648033)
- Testing
- Atovaquone Oral Suspension, Standard of care chemotherapy, Standard of care radiotherapy
- Where
- 3 sites in United Kingdom
- Volunteers
- 21 people
- Sponsor
- University of Oxford
Type 2 Diabetes Mellitus in Obese
REmote SUpport for Low-Carbohydrate Treatment of Type 2 Diabetes
Excess adiposity is a key causal factor in developing type 2 diabetes and weight loss improves glycaemia and can put diabetes in to remission. There is evidence that low carbohydrate diets also reduce glycaemia.
- Trial name
- RESULT (NCT04916314)
- Testing
- Low Carbohydrate diet
- Where
- United Kingdom
- Volunteers
- 115 people
- Sponsor
- University of Oxford
Psoriatic Arthritis
Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial
SPEED is a three arm interventional trial nested within a cohort (Trials Within Cohorts or TWiCs design). This tests more aggressive early therapy in patients newly diagnosed with moderate to severe PsA.
- Trial name
- SPEED (NCT03739853)
- Testing
- Methotrexate, Sulfasalazine, Leflunomide
- Where
- United Kingdom
- Volunteers
- 192 people
- Sponsor
- University of Oxford
Stroke
Improving Sleep in Rehabilitation After Stroke
This study evaluates the efficacy of digital cognitive behavioural therapy for insomnia (Sleepio) in chronic stroke survivors. Half of the participants will receive access to the digital (online) programme, half will receive a…
- Trial name
- INSPIRES (NCT04272892)
- Testing
- Digital cognitive behavioural therapy for insomnia, Sleep hygiene information
- Where
- United Kingdom
- Volunteers
- 86 people
- Sponsor
- University of Oxford